首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Handbook of experimental pharmacology

缩写:

ISSN:0171-2004

e-ISSN:

IF/分区:0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引2218
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Christina Friedrich Christina Friedrich
Quantitative systems pharmacology (QSP) is a modeling approach employed in drug research and development that combines mechanistic representations of biological processes with drug pharmacology to deepen biological understanding and predict...
Hanwen Wang,Theinmozhi Arulraj,Alberto Ippolito et al. Hanwen Wang et al.
Despite an increasing number of clinical trials, cancer is one of the leading causes of death worldwide in the past decade. Among all complex diseases, clinical trials in oncology have among the lowest success rates, in part due to the high...
Susana Zaph,Randolph J Leiser,Mengdi Tao et al. Susana Zaph et al.
Quantitative Systems Pharmacology (QSP) models offer a promising approach to extrapolate drug efficacy across different patient populations, particularly in rare diseases. Unlike conventional empirical models, QSP models can provide a mecha...
Ozra Tabatabaei-Malazy,Bayan Azizi,Mohammad Abdollahi Ozra Tabatabaei-Malazy
Neurocognitive disorders are characterized by a decline in various components of cognitive function, resulting in a high rate of morbidity and mortality. Despite multiple efforts, there is still a lack of practical preventive and therapeuti...
Valérie B Schini-Kerth,Ibrahima Diouf,Hira Muzammel et al. Valérie B Schini-Kerth et al.
Maintaining good vascular health is a major component in healthy ageing as it reduces the risk of cardiovascular diseases. Endothelial dysfunction, in particular, is a key mechanism in the development of major cardiovascular diseases includ...
Thomas Hirse Thomas Hirse
Public-private partnerships in drug R&D have great potential for driving innovation. They can bridge between excellent fundamental research and development and commercialization of innovative medicines to address unmet needs for the therapy...
Anita Seshire,Yukun Duan,Kahina Lang Anita Seshire
mRNA and targeted delivery of mRNA carry the promise to enable targeted treatment of undruggable diseases with high unmet medical needs. The transient nature of mRNA opens options for safe influencing of protein biology, immune responses, a...
R L A de Vrueh,J S B de Vlieger,K M Orrling et al. R L A de Vrueh et al.
Public-Private Partnerships (PPPs) have been crucial in medicine research and development (R&D) for decades. Initially, PPPs involved private and academic innovators working in bilateral collaborations to advance pharmaceutical innovation. ...
Cherry L Wainwright,Sarah K Walsh Cherry L Wainwright
The use of Cannabis sativa by humans dates back to the third millennium BC, and it has been utilized in many forms for multiple purposes, including production of fibre and rope, as food and medicine, and (perhaps most notably) for its psych...
Flavia-Bianca Cristian,Christian Tidona,Thomas Rückle Flavia-Bianca Cristian
In the evolving landscape of biomedical research, the convergence of molecular biology and translational medicine has ushered in a new era of pharmaceutical innovation. This paradigm shift, characterized by significant advances in targeted ...